First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan

Abstract EN

Aims.

Patients with chronic kidney disease (CKD) and Helicobacter pylori (H.

pylori) infection have a higher incidence of gastroduodenal diseases and therefore are recommended to receive eradication therapies.

This study aimed to assess the efficacy of a 7-day standard triple therapy in patients with CKD (eGFR < 60 ml/min/1.73 m2) and to investigate the clinical factors influencing the success of eradication.

Methods.

A total of 758 patients with H.

pylori infection receiving a 7-day standard first-line triple therapy between January 1, 2013, and December 31, 2014, were recruited.

Patients were divided into two groups: CKD group (N=130) and non-CKD group (N=628).

Results.

The eradication rates attained by the CKD and non-CKD groups were 85.4% and 85.7%, respectively, in the per-protocol analysis (p=0.933).

The eradication rate in CKD stage 3 was 84.5% (82/97), in stage 4 was 88.2% (15/17), and in those who received hemodialysis was 87.5% (14/16).

There were no significant differences in the various stages of CKD (p=0.982).

The adverse events were similar between the two groups (3.1% versus 4.6%, p=0.433).

Compliance between the two groups was good (100.0% versus 99.8%, p=0.649).

There was no significant clinical factor influencing the H.

pylori eradication rate in the non-CKD and CKD groups.

Conclusions.

This study suggests that the H.

pylori eradication rate and adverse rate in patients with CKD are comparable to those of non-CKD patients.